Sign in
CompletedNo phase

Controlled Arterial Protection to Ultimately Remove Embolic Material

Key facts

Who runs it
EmStop Inc
Where
Asheville and Nashville, United StatesSee the 2 sites
Trial code
Status
Completed
People taking part
15 people enrolled
Started
27 Dec 2023
Ended
14 Oct 2024
Type of study
Interventional
Treatments tested
  • The EmStop Embolic Protection System (EmStop System)
Record updated
29 April 2025

Who can take part

Age
21 years to 90 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Clinical \& Angiographic Inclusion Criteria
  • Between 21 and 90 years of age at the time of consent
  • Meets FDA approved indications for transcatheter aortic valve replacement (TAVR) procedure on a native aortic valve using a commercially available Abbott or Medtronic transcatheter heart valve
  • Willing and able to provide written informed consent and written HIPAA authorization prior to initiation of study procedures
  • Willing and able to comply with the protocol-specified procedures and assessments
  • Subject anatomy is compatible with correct device deployment and positioning with:; Ability to achieve access with a 21 French equivalent femoral access sheath; Ascending aorta length ≥8 cm; Ascending aorta/aortic arch diameter is ≥25 or ≤40 mm; Ascending aorta or aortic arch exhibits ≤ Grade 1 atheromatous disease and limited wall calcification

Who cannot take part

  • Previously implanted aortic or mitral valve bioprosthesis
  • Planned to undergo any other cardiac surgical or interventional procedure (e.g., concurrent coronary revascularization) during the TAVR procedure or within 30 days prior to the TAVR procedure. NOTE: Diagnostic cardiac catheterization is permitted up until baseline MRI is obtained. Once baseline MRI is obtained, no additional intra-aortic or intracardiac procedure may occur
  • Documented history of stroke or TIA within the prior 6 months, or any prior stroke with a permanent major disability or deficit (NIHSS >1 at baseline)
  • History of intolerance, allergic reaction, or contraindication to any of the study medications, including heparin, aspirin, clopidogrel, or a sensitivity to contrast media or anesthesia that cannot be adequately pre-treated
  • Currently participating in another drug or device clinical study
  • Hepatic failure (Child-Pugh class C)
  • Acute myocardial infarction within 30 days of the planned index procedure
  • Known allergy or sensitivity to nickel-titanium
  • History of bleeding diathesis or a coagulopathy
  • Renal failure, defined as estimated glomerular filtration rate (eGFR) <30 mL/min
  • Left ventricular ejection fraction ≤30% within 3 months prior to procedure
  • Active endocarditis or ongoing systemic infection, defined as fever (>38°C) and/or white blood cell (WBC) >15,000 IU
  • Known or suspected to be pregnant, or is lactating; female subjects of child-bearing potential must have a negative serum or urine pregnancy test within 48 hours prior to the index study procedure
  • Requires urgent or emergent TAVR procedure
  • Contraindicated to MRI
  • Hypercoagulable state that cannot be corrected by additional periprocedural heparin
  • Undergoing therapeutic thrombolysis
  • Any other clinical reason, as deemed by the investigators of the study, by which the patient would not be an appropriate candidate for the study
  • Vulnerable subject populations (e.g., incarcerated or cognitively challenged adults)

Where in United States

  • Mission HealthAsheville, United States
  • Centennial Medical CenterNashville, United States

About the trial

What the trial wants to find out

The objective of this study is to demonstrate device feasibility, safety and investigate performance of the EmStop Embolic Protection System when used as indicated in 15 subjects at 2 investigational sites in the U.S.

The group in the trial

  • EmStop Embolic Protection SystemTreatment being tested

    Transcatheter aortic valve replacement (TAVR) procedures with the EmStop Embolic Protection System (EmStop System).

    Treatment: The EmStop Embolic Protection System (EmStop System)

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
29 April 2025